Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday October 22 10:33 AM EDT
Dr. Sharon Hillier, of Magee-Womens Research Institute and the University of Pittsburgh, has tested Demeter Peptidyl MIM(TM) D2A21 against several common STD pathogens. Dr. Hillier is an internationally recognized researcher on STDs and Lactobacillus crispatus, the "good bacteria" necessary for a healthy vaginal environment. Her studies demonstrated in vitro that D2A21 was effective against gonorrhea and Trichomonas. Particularly significant was the fact that D2A21 was effective at concentrations that do not negatively effect Lactobacillus crispatus. Additionally, D2A21 remained effective in the presence of 10 percent blood serum and at pH's ranging from 4 to 8. Dr. Hillier presented her results at the 37th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, held recently in Toronto, Canada.
According to Dr. Hillier, "There is a big push in the U.S. from medical research centers and government agencies to provide effective and accessible prophylactic products for women to protect themselves from sexually transmitted infections". Dr. Hillier is the recipient of funding from the National Institutes of Health (NIH) and her research focuses on testing agents that prevent STDs and also on the role of a healthy vaginal environment for prevention of diseases. Hillier added, "There is an interest in my laboratory in testing active compounds, like D2A21, as a potential topical microbicide for the prevention of STDs. STD infections are often the cause of serious reproductive problems in women. It is only through the development of new and more effective prophylactic products that women will be able to protect their reproductive health."
The increasing incidence of STDs and women's need to protect their reproductive health are impetus for development of novel methods of STD prevention. There are approximately 6 million American women infected each year with Chlamydia. According to the World Health Organization (WHO), in 1996 there were 22 million people worldwide infected with HIV, 62 million new cases of gonorrhea and 170 million new cases of Trichomonas.
Demeter was recently awarded a Phase I SBIR grant from the National Institutes of Health (NIH) for $100,000 to conduct pre-clinical tests necessary for development of an intravaginally administered STD prophylactic product.
Demeter BioTechnologies, Ltd. has pioneered the design and development of synthetic molecules for anti-infective and anti-cancer applications. Its unique peptide molecules have structures based on principals discovered in naturally occurring peptides, but have greater potency with reduced toxicity.
This press release includes forward looking statements which reflect management's current views as to the Company's scientific results, collaborative arrangements, product developments, and other future events and operations. There are considerable risks and challenges to be overcome before a product is commercially viable and regulatory approval obtained. Other companies may develop competing technologies and there is no assurance that the Company's patent position is adequate. Actual results may differ materially from these forward looking statements. The Company disclaims any intent or obligation to update these forward looking statements.
For more information, contact Richard D. Ekstrom, President, Demeter BioTechnologies, Ltd. at (919) 682-7181 or Michael Derrick of Progressive Media Group at (800) 262-9798.
SOURCE Demeter BioTechnologies, Ltd.
Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
971022
PR971015
Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .